Press release content from Globe Newswire. The AP news staff was not involved in its creation.
DARPA and JPEO-CBRND Award $37.6M to The Wistar Institute and Collaborators at INOVIO, .
The Wistar InstituteDecember 15, 2020 GMT
PHILADELPHIA, Dec. 15, 2020 (GLOBE NEWSWIRE) A team of scientists from The Wistar Institute, INOVIO, AstraZeneca, the Perelman School of Medicine at the University of Pennsylvania, and Indiana University has received a $37.6 million award over two years from the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for rapid preclinical development and translational studies of DNA-encoded monoclonal antibodies (DMAbs) as countermeasures for COVID-19.
Press release content from Business Wire. The AP news staff was not involved in its creation.
SAB Biotherapeutics Announces New Appointments to its Board of Directors
December 16, 2020 GMT
SIOUX FALLS, S.D. (BUSINESS WIRE) Dec 16, 2020
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors.
“We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a pivotal time as we continue to advance a new class of immunotherapies that leverage the native hu
SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces New Appointments to its Board of Directors
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors. We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise, said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. Both Drs. Mohindru and Turner are joining SAB at a pivotal time as we continue to advance a new class of immunotherapies that leverage the native human immune response and match the evolution of human disease. We look forward to their contributions as we develop our robust pipeline, spanning
INOVIO To Develop DMAb Candidates To Treat COVID-19 With DARPA Funding
WASHINGTON (dpa-AFX) - Biotechnology company INOVIO (INO) said Tuesday it will develop DNA-encoded monoclonal antibody or dMAb candidates to treat COVID-19 with funding from the U.S. Defense Advanced Research Projects Agency or DARPA, and the Department of Defense s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense or JPEO-CBRND.
InOVIO said that the company and a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant to use INOVIO s DNA-encoded monoclonal antibody or dMAb technology to develop anti-SARS-CoV-2-specific dMAbs.
Credit: The Wistar Institute
PHILADELPHIA (Dec. 15, 2020) A team of scientists from The Wistar Institute, INOVIO, AstraZeneca, the Perelman School of Medicine at the University of Pennsylvania, and Indiana University has received a $37.6 million award over two years from the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for rapid preclinical development and translational studies of DNA-encoded monoclonal antibodies (DMAbs) as countermeasures for COVID-19.
DMAbs, unlike conventional therapeutic antibodies, are administered as genetic blueprints that instruct the patient s body to build its own highly specific antibodies against pathogens, such as bacteria and viruses, and as immunotherapeutics for cancer. Conceptually DMAbs have advantages over traditional monoclonal antibodies in scale-up and delivery, which would rapidly benefit large populations.